×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Codiak Biosciences files for bankruptcy
Fierce Biotech
Another biotech bites the dust. This time it's Codiak BioSciences, whose attempts to deliver exosome-based therapeutics have reached the end...
14 months ago
Cash-strapped biotech firm Codiak files for bankruptcy protection
Reuters
Codiak BioSciences Inc said on Monday it has filed for U.S. bankruptcy protection in the latest blow to the struggling drug developer's...
14 months ago
Codiak BioSciences to Pursue Asset Sale through Voluntary Chapter 11 Process
Yahoo Finance
CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ: CDAK), a clinical-stage biopharmaceutical company...
14 months ago
Jazz Pharmaceuticals and Codiak BioSciences Announce Strategic Collaboration to Research, Develop and ...
PR Newswire
PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Codiak BioSciences, Inc. today announced that the companies have entered into a...
64 months ago
Codiak BioSciences Files for Chapter 11 Bankruptcy Protection
WSJ
Codiak BioSciences Inc. said Monday that it has voluntarily filed for chapter 11 bankruptcy protection in the U.S. Bankruptcy Court for the...
14 months ago
Codiak BioSciences To File For Chapter 11
Contract Pharma
Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class...
14 months ago
ARCH Venture Partners, Flagship Ventures and MD Anderson collaborate to launch Codiak BioSciences
MD Anderson Cancer Center
Company secures $80-plus million in committed funding to develop exosome-based therapeutic and diagnostic products...
102 months ago
Codiak Names Yalonda Howze Executive Vice President, Chief Legal Officer
Business Wire
Codiak BioSciences, Inc., a company at the forefront of advancing engineered exosomes as a new class of biologic medicines, today announced...
46 months ago
Codiak's publication highlights the ability of exoASO-STAT6 to selectively target tumor-associated macrophages
News-Medical
Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class...
27 months ago
IPO Update: Codiak BioSciences Proposes IPO Terms (OTCMKTS:CDAKQ-DEFUNCT-712759)
Seeking Alpha
Summary. Codiak BioSciences has filed to raise $82.5 million in an IPO. The firm is advancing a pipeline of exosome-based treatment...
43 months ago